Ed Gillis, CEO of Revolution Contraceptives, the social venture company tasked with developing Vasalgel for Parsemus Foundation, traveled to Paris this spring to exchange ideas with other male contraceptive innovators at the second International Congress on Male Contraception. He aimed to network with others in the field, learn about other male contraceptives in development, and… Read more
Vasalgel made the Daily Beast’s list of the medical advances in 2017 that “are going to not only dramatically transform how we think about the birds and the bees but also the very way we think about reproduction.” In the December 25, 2017 article by senior science editor Tanya Basu, Vasalgel was heralded as the frontrunner… Read more
Usually, the development of a medical device happens out of the public eye, but in our case, we have shared information with the public and have gathered a large and wonderful group of Vasalgel followers. Their support enables the Vasalgel team to demonstrate that men are ready and willing to use a new male contraceptive…. Read more
How will the availability of new male contraceptive options impact the number of unintended pregnancies? Researchers recently created a model to answer that question in a paper published in Contraception. They focused the analysis on three countries (United States, South Africa and Nigeria) which differed by the type and rate of contraceptive use. By analyzing… Read more
This year has been especially busy for the Vasalgel program — and ramping up to clinical trials over the next year will require all our focus. This is a critical time in the development pathway. We will do our best to communicate our progress to you and will keep the FAQ updated. You can always… Read more
Good news for Vasalgel! Ed Gillis has joined the team as CEO of Revolution Contraceptives, LLC, the social venture company that is developing Vasalgel under the umbrella of Parsemus Foundation. Ed has a history of leadership in early-stage medical companies, most recently as CEO and CTO at ReVENT Medical, Inc. — a company he founded…. Read more
You can see an “inside view” of Vasalgel in action thanks to this video representation with animation by Filip Spasev and Will Justice. The project was led by Abraxas Adams, who heads up creative and technical services at Parsemus Foundation.
Successful reversal of Vasalgel male contraceptive in rabbits For immediate release: Vasalgel’s prevention of sperm transport in the vas deferens for 14 months was reversed through an injection of sodium bicarbonate. Sperm concentration and motility returned to baseline. Results of a study of a promising new male contraceptive called VasalgelTM were published today in Basic… Read more
Vasalgel given to 16 monkeys resulted in 100% successful contraception — no pregnancies after 1 to 2 years. The results, published in Basic and Clinical Andrology, also showed that Vasalgel was well-tolerated in the monkeys, who had fewer complications than a control group receiving vasectomy. The results are important to the development of Vasalgel as a… Read more
Press Release Monday, Feb. 6, 2017 20:00 EST New contraceptive Vasalgel provides effective birth control in rhesus monkey groups for more than one year: report from California National Primate Research Center Results of a study of Vasalgel in rhesus macaques were published today in Basic and Clinical Andrology. Vasalgel is being developed by a social… Read more